(Q48924925)

16 February 2018

title

Lamotrigine: clinical experience in 200 patients with epilepsy with follow-up to four years. (English)

1 reference

16 February 2018

1 reference

N Buchanan

1

1 reference

16 February 2018

publication date

1 September 1996

1 reference

16 February 2018

Seizure-European Journal of Epilepsy

published in

1 reference

16 February 2018

volume

5

1 reference

16 February 2018

issue

3

1 reference

16 February 2018

page(s)

209-214

1 reference

16 February 2018

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

1 reference

7 January 2021

Clinical use of lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine in primary generalised epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine for generalised epilepsies

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Acute effects of lamotrigine (BW430C) in persons with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Sodium valproate acutely inhibits lamotrigine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Outcomes of add-on treatment with lamotrigine in partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Epilepsy with myoclonic absences

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine as an add-on drug in typical absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine: clinical experience in 93 patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine in treatment of 120 children with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Lamotrigine use in twelve patients with the Lennox-Gastaut Syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

Vigabatrin use in 72 patients with drug-resistant epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980038-0

7 January 2021

10.1016/S1059-1311(96)80038-0

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018